TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16686906

Group type: EXPERIMENTAL
Intervention: Severe and frequent headaches
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Migraine without aura
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: TCD velocities
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Brain MRI abnormalities
Number of subjects: 56
Study: 15490785

Group type: EXPERIMENTAL
Intervention: Histamine iontophoresis (1 percent histamine dihydrochloride)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Direct Current (without histamine)
Number of subjects: 20
Study: 11447507

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone
Number of subjects: 617

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 617
Study: 9429740

Group type: EXPERIMENTAL
Intervention: Direct administration into the duodenum (40 mg)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Oral administration (40 mg)
Number of subjects: 4
Study: 8510982

Group type: EXPERIMENTAL
Intervention: 0.5% delmopinol HCl
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 15791755

Group type: EXPERIMENTAL
Intervention: Interviewer controls
Number of subjects: 0

Group type: COMPARATOR
Intervention: Past studies
Number of subjects: 0
Study: 31371114

Group type: EXPERIMENTAL
Intervention: Armolipid Plus™ (AP)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study: 30526512

Group type: EXPERIMENTAL
Intervention: Insufficient fruits and vegetables consumption
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Insufficient physical activity
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Tobacco use
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Harmful alcohol drinking
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Primary level education
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Age group 20-34 years
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Highest wealth index
Number of subjects: 426
Study: 26330379

Group type: EXPERIMENTAL
Intervention: Nifedipine maintenance tocolysis
Number of subjects: 170

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study: 24794721

Group type: EXPERIMENTAL
Intervention: Subcutaneous peginterferon beta‐1a 125 μg every 2 weeks
Number of subjects: 1516

Group type: EXPERIMENTAL
Intervention: Subcutaneous peginterferon beta‐1a 125 μg every 4 weeks
Number of subjects: 1516

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1516

Group type: EXPERIMENTAL
Intervention: Peginterferon every 2 weeks
Number of subjects: 1516

Group type: EXPERIMENTAL
Intervention: Peginterferon every 4 weeks
Number of subjects: 1516
Study: 21777510

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) at 135 Hz (90-μs pulsewidth)
Number of subjects: 8
Study: 20484128

Group type: EXPERIMENTAL
Intervention: Letrozole (aromatase inhibitor) to lower estradiol and increase testosterone (group T)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Letrozole plus E(2) patches to lower testosterone and raise estradiol (group E)
Number of subjects: 20
Study: 18713923

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Alpha-2 adrenergic blockade with yohimbine
Number of subjects: 56
Study: 16477766

Group type: EXPERIMENTAL
Intervention: Vitamin E (200 IU/day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 12027070

Group type: EXPERIMENTAL
Intervention: 100 microg albuterol/HFA 134a
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: 200 microg albuterol/HFA 134a
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: 400 microg albuterol/HFA 134a
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: 100 microg albuterol/CFC
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: 200 microg albuterol/CFC
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo/HFA 134a
Number of subjects: 63
Study: 11305737

Group type: EXPERIMENTAL
Intervention: Iloprost (2 ng/min/kg)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Alprostadil (4.4 ng/min/kg)
Number of subjects: 35
Study: 8868276

Group type: EXPERIMENTAL
Intervention: Words condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pictures condition
Number of subjects: 0
Study: 1947972

Group type: EXPERIMENTAL
Intervention: Articaine with 1:100,000 epinephrine (EPI)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Lidocaine with 1:100,000 epinephrine (EPI)
Number of subjects: 74
Study: 6682667

Group type: EXPERIMENTAL
Intervention: Maalox 70 (4 x 10 ml/die)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 31612909

Group type: EXPERIMENTAL
Intervention: atezo + nab‐P
Number of subjects: 65

Group type: COMPARATOR
Intervention: plac + nab‐P
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: atezo + nab‐P (PD-L1-positive subgroup)
Number of subjects: 65

Group type: COMPARATOR
Intervention: plac + nab‐P (PD-L1-positive subgroup)
Number of subjects: 65
Study: 28650192

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Panic-Focused Psychodynamic Psychotherapy (PFPP)
Number of subjects: 161
Study: 26011779

Group type: EXPERIMENTAL
Intervention: Armodafinil (150‐250 mg/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 23230975

Group type: EXPERIMENTAL
Intervention: everolimus <3 ng/mL
Number of subjects: 556

Group type: EXPERIMENTAL
Intervention: everolimus ≥ 12 ng/mL
Number of subjects: 556

Group type: EXPERIMENTAL
Intervention: everolimus 3-8 ng/mL and CsA <100 ng/mL
Number of subjects: 556

Group type: EXPERIMENTAL
Intervention: very low or very high everolimus trough concentrations
Number of subjects: 556
Study: 22105589

Group type: EXPERIMENTAL
Intervention: 50 mg of modafinil (3 doses, given 8 hourly)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 100 mg of modafinil (3 doses, given 8 hourly)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 200 mg of modafinil (2 doses) plus placebo (1 dose, given 8 hourly)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (3 doses, given 8 hourly)
Number of subjects: 80
Study: 19761889

Group type: EXPERIMENTAL
Intervention: Mashed potato with 1% HV‐HPMC
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Mashed potato with 2% HV‐HPMC
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Mashed potato with 4% HV‐HPMC
Number of subjects: 15

Group type: COMPARATOR
Intervention: Standard mashed potato
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Mashed potato with HV‐HPMC (all doses)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: HV‐HPMC doses
Number of subjects: 15
Study: 16490891

Group type: EXPERIMENTAL
Intervention: molgramostim (3 microg/kg for 4 days)
Number of subjects: 58

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 58
Study: 11834140

Group type: EXPERIMENTAL
Intervention: Glycyrrhetinic acid (GA) 500 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 10613410

Group type: EXPERIMENTAL
Intervention: Ultra-fine whole-grain wheat flour (UFWF)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Conventional whole-grain wheat flour (WWF)
Number of subjects: 26

Group type: COMPARATOR
Intervention: White bread
Number of subjects: 26

Group type: COMPARATOR
Intervention: Glucose solution
Number of subjects: 26
Study: 7583255

Group type: EXPERIMENTAL
Intervention: Deviant stimuli presented alone
Number of subjects: 8

Group type: COMPARATOR
Intervention: Deviant stimuli presented among standards
Number of subjects: 8
Study: 2303961

Group type: EXPERIMENTAL
Intervention: Active stimulators (experimental group)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Dummy stimulators (control group)
Number of subjects: 44
Study: 434280

Group type: EXPERIMENTAL
Intervention: High status interviewers (identified physicians)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low status interviewers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lay interviewers
Number of subjects: 0
Study: 6645593

Group type: EXPERIMENTAL
Intervention: Percutaneous removal of IAB (Group I)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Surgical removal of IAB (Group II)
Number of subjects: 38
Study: 31356267

Group type: EXPERIMENTAL
Intervention: Telemedicine-based home management program (THMP)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 106
Study: 29429541

Group type: EXPERIMENTAL
Intervention: Low-fat (LF) diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moderately high-protein (MHP) diet
Number of subjects: 0
Study: 28300813

Group type: EXPERIMENTAL
Intervention: cytoflavin
Number of subjects: 74

Group type: COMPARATOR
Intervention: comparison group (control)
Number of subjects: 74
Study: 23804555

Group type: EXPERIMENTAL
Intervention: Neuropsychological rehabilitation (computer‐based attention and working memory retraining, psychoeducation, strategy learning, psychological support)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 102
Study: 22711171

Group type: EXPERIMENTAL
Intervention: Metformin (1000 mg/day)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 20576419

Group type: EXPERIMENTAL
Intervention: Mannitol 240 mg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Mannitol 480 mg
Number of subjects: 7

Group type: COMPARATOR
Intervention: Cough control (no mannitol)
Number of subjects: 7
Study: 17591126

Group type: EXPERIMENTAL
Intervention: Propofol administration with bispectral index monitoring (group B)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Routine anaesthesia with propofol at target concentration (group C)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Group C (control)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Group B (intervention)
Number of subjects: 20
Study: 16230244

Group type: EXPERIMENTAL
Intervention: 4-hour clamping drainage (group 1)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Nonclamping drainage (group 2)
Number of subjects: 89
Study: 12453546

Group type: EXPERIMENTAL
Intervention: 5 mg oral morphine four times daily for 4 days (2.5 mg if creatinine > 200 micromol/l)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 10747212

Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 54

Group type: COMPARATOR
Intervention: Oxycodone
Number of subjects: 54
Study: 7793547

Group type: COMPARATOR
Intervention: 0.125% bupivacaine alone (control group)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Alfentanil at 266 micrograms.h‐1
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Alfentanil at 400 micrograms.h‐1
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Diamorphine at 400 micrograms.h‐1
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Diamorphine at 533 micrograms.h‐1
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: All opioid groups (alfentanil and diamorphine)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (0.125% bupivacaine alone)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Diamorphine at highest dose (533 micrograms.h‐1)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 120
Study: 1822492

Group type: EXPERIMENTAL
Intervention: Intracervical dinoprostone 0.5 mg gel (Group 1, n = 24)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intracervical administration of PGE2 1.5 mg on Surgicel (Group 2, n = 26)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intracervical dinoprostone 0.5 mg gel (Group 3, n = 28)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Administration of PGE2 2.25 mg on a Spongel (Group 4, n = 22)
Number of subjects: 100
Study: 7333752

Group type: EXPERIMENTAL
Intervention: Trained subjects
Number of subjects: 29

Group type: COMPARATOR
Intervention: Sedentary subjects
Number of subjects: 29
Study: 31498469

Group type: EXPERIMENTAL
Intervention: Testosterone therapy (TTh) injections (>12 injections)
Number of subjects: 189491

Group type: EXPERIMENTAL
Intervention: Testosterone therapy (TTh) topical gels (>330 days supply)
Number of subjects: 189491

Group type: EXPERIMENTAL
Intervention: Testosterone therapy (injection and gel) in nondiabetics
Number of subjects: 189491

Group type: EXPERIMENTAL
Intervention: Testosterone therapy injections in diabetics
Number of subjects: 189491
Study: 29800370

Group type: EXPERIMENTAL
Intervention: Live-attenuated tetravalent dengue vaccine (TDV)
Number of subjects: 0
Study: 27790333

Group type: EXPERIMENTAL
Intervention: Lactocare® (Synbiotic containing 1 billion CFU/Capsule of various probiotics)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Lactocare® (Synbiotic)
Number of subjects: 72
Study: 24588298

Group type: EXPERIMENTAL
Intervention: Expressive writing
Number of subjects: 149

Group type: COMPARATOR
Intervention: Control writing
Number of subjects: 149
Study: 22234929

Group type: EXPERIMENTAL
Intervention: Guanfacine (up to 3 mg)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 19556719

Group type: EXPERIMENTAL
Intervention: 100 mg aspirin + 300 mg rebamipide
Number of subjects: 20

Group type: COMPARATOR
Intervention: 100 mg aspirin + placebo
Number of subjects: 20
Study: 17886708

Group type: EXPERIMENTAL
Intervention: Concomitant chemotherapy and radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alternant chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with hematologic support
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Whole-brain prophylactic radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New targeted therapy agents or immunotherapeutic approaches
Number of subjects: 0
Study: 15793155

Group type: EXPERIMENTAL
Intervention: Oral doxycycline at 200 mg every 24 h
Number of subjects: 17
Study: 12165125

Group type: EXPERIMENTAL
Intervention: Bond‐1
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Prime & Bond NT
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Etch & Prime 3.0
Number of subjects: 30
Study: 9861129

Group type: EXPERIMENTAL
Intervention: Saline-filled LMA cuff
Number of subjects: 20

Group type: COMPARATOR
Intervention: Air-filled LMA cuff
Number of subjects: 20
Study: 8519714

Group type: EXPERIMENTAL
Intervention: Thoracic patient-controlled epidural fentanyl
Number of subjects: 30

Group type: COMPARATOR
Intervention: Lumbar patient-controlled epidural fentanyl
Number of subjects: 30
Study: 2194047

Group type: EXPERIMENTAL
Intervention: Progesterone 400 mg
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Progesterone 800 mg
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study: 369623

Group type: EXPERIMENTAL
Intervention: L-5-hydroxytryptophan (L-5HTP) with carbidopa
Number of subjects: 31

Group type: COMPARATOR
Intervention: Neuroleptics
Number of subjects: 31
Study: 30543274

Group type: EXPERIMENTAL
Intervention: Core Stability Training (CST)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 20
Study: 28122161

Group type: EXPERIMENTAL
Intervention: Education empowerment program
Number of subjects: 108

Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 108
Study: 25265255

Group type: EXPERIMENTAL
Intervention: Tacrolimus once-daily formulation (Tac-OD)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Tacrolimus twice-daily formulation (Tac-TD)
Number of subjects: 247
Study: 23448746

Group type: EXPERIMENTAL
Intervention: ST-36 acupressure
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham acupressure (Control)
Number of subjects: 60
Study: 21366473

Group type: EXPERIMENTAL
Intervention: Intensive therapy (targeting a glycated hemoglobin level below 6.0%)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard therapy (targeting a glycated hemoglobin level of 7 to 7.9%)
Number of subjects: 0
Study: 18298579

Group type: EXPERIMENTAL
Intervention: Didanosine enteric-coated capsules (ddI-EC) administered in a fasted state (group 1)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Didanosine enteric-coated capsules (ddI-EC) administered with food (group 2)
Number of subjects: 21
Study: 16946615

Group type: EXPERIMENTAL
Intervention: AmF/SnF2 mouthwash
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rinsing with tap water
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Expectorating only
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (F‐free periods)
Number of subjects: 0
Study: 12921431

Group type: EXPERIMENTAL
Intervention: Task and response set switches in blocked condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Task and response set switches in random condition with brief cue-to-target interval
Number of subjects: 0
Study: 10918483

Group type: EXPERIMENTAL
Intervention: DNA/liposome formulation (plasmid DNA expressing CFTR cDNA complexed with DC‐Chol/DOPE cationic liposomes)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 9005590

Group type: EXPERIMENTAL
Intervention: Mepartricin 150,000 U (40 mg) administered once-a-day in the evening for 60 days
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 1419290

Group type: EXPERIMENTAL
Intervention: 3M (mitozantrone 6.5 mg/m2 q 21 days, methotrexate 30 mg/m2 q 21 days, mitomycin C 6.5 mg/m2 q 42 days)
Number of subjects: 105

Group type: COMPARATOR
Intervention: 2M (as 3M but without mitomycin C)
Number of subjects: 105
Study: 6732324

Group type: EXPERIMENTAL
Intervention: Open peritoneal lavage
Number of subjects: 118

Group type: COMPARATOR
Intervention: Closed peritoneal lavage
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Supraumbilical approach
Number of subjects: 118

Group type: COMPARATOR
Intervention: Infraumbilical approach
Number of subjects: 118
Study: 31370792

Group type: EXPERIMENTAL
Intervention: Multi-component intervention A (advanced) including nutritional counseling, physical activity, cognitive training, optimization of medication, management of vascular risk factors, social activity, and specific interventions targeting grief and depression
Number of subjects: 1152

Group type: COMPARATOR
Intervention: General health advice and GP treatment as usual (Intervention B)
Number of subjects: 1152
Study: 30205830

Group type: EXPERIMENTAL
Intervention: Collaborative care model with trained PHC staff and community-based 'Healthy Living groups' co-led by Ashas using cognitive-behavioral strategies.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 0
Study: 27876035

Group type: EXPERIMENTAL
Intervention: Tailored DVD intervention provided preoperatively and used throughout the postoperative period
Number of subjects: 156

Group type: COMPARATOR
Intervention: Usual treatment
Number of subjects: 156
Study: 25691263

Group type: EXPERIMENTAL
Intervention: Early intubation (within 48 hours)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Late intubation (after 48 hours)
Number of subjects: 175
Study: 23654022

Group type: EXPERIMENTAL
Intervention: Exploratory Factor Analysis (EFA)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Confirmatory Factor Analysis (CFA)
Number of subjects: 250
Study: 21482863

Group type: EXPERIMENTAL
Intervention: Becaplermin gel (0.1% in hydrogel), applied once daily for 8 weeks
Number of subjects: 64

Group type: COMPARATOR
Intervention: Hydrogel dressing, applied once daily for 8 weeks
Number of subjects: 64

Group type: COMPARATOR
Intervention: Becaplermin gel and Hydrogel dressing
Number of subjects: 64
Study: 19917839

Group type: EXPERIMENTAL
Intervention: Trastuzumab (6 mg/kg every 3 weeks for 1 year)
Number of subjects: 3010

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 3010
Study: 17029996

Group type: EXPERIMENTAL
Intervention: GH and T (GHT)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: GH
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: T
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: GHT
Number of subjects: 69

Group type: COMPARATOR
Intervention: P (placebo)
Number of subjects: 69
Study: 12644426

Group type: EXPERIMENTAL
Intervention: Continuous i.v. diltiazem 1 micro g kg(‐1) min(‐1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 30
Study: 10709897

Group type: EXPERIMENTAL
Intervention: Fluid regime A (60 ml/kg on day 1, increasing to 150 ml/kg over the first week)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Fluid regime B (approximately 20% less fluid than regime A over the first week)
Number of subjects: 168
Study: 9090342

Group type: EXPERIMENTAL
Intervention: Brief trauma/grief-focused psychotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not treated with psychotherapy
Number of subjects: 0
Study: 7529606

Group type: EXPERIMENTAL
Intervention: G‐CSF and GM‐CSF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Erythropoietin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interleukin‐3, interleukin‐6, and interleukin‐11
Number of subjects: 0
Study: 3395027

Group type: EXPERIMENTAL
Intervention: Cefamandole 1-gram preoperative dose followed by 4 additional postoperative doses at 6-hour intervals
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Cefamandole 2-gram doses
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Cefoxitin 2-gram doses
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Cefamandole (5-gram course)
Number of subjects: 150
Study: 30016417

Group type: EXPERIMENTAL
Intervention: Active-suspension seat
Number of subjects: 40

Group type: COMPARATOR
Intervention: Passive air-suspension seat (control)
Number of subjects: 40
Study: 28672073

Group type: EXPERIMENTAL
Intervention: Exercise intervention (two doses for 12 weeks)
Number of subjects: 122
Study: 26582144

Group type: EXPERIMENTAL
Intervention: Commercially produced Scoparia dulcis porridge (SDC) for 3 days/week for three months
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (any other food)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Commercially produced Scoparia dulcis porridge (SDC)
Number of subjects: 35
Study: 24909528

Group type: EXPERIMENTAL
Intervention: Basic science instruction
Number of subjects: 51

Group type: COMPARATOR
Intervention: Clinically focused instruction
Number of subjects: 51
Study: 22680836

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938 (4 × 10^8 colony-forming units/die)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 20145986

Group type: EXPERIMENTAL
Intervention: Immediate Treatment (IT) group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist Control group
Number of subjects: 0